NFE2L2 and head and neck cancer: NRF2 activation also contributes to ferroptosis resistance of head and neck cancer cells; importantly, in vivo inhibition of the NRF2 pathway sensitized ferroptosis-resistant head and neck cancers to 50 mg/kg of artesunate, a ferroptosis inducer (130).